Multidrug-resistant Staphylococcus hominis subsp. novobiosepticus causing septicemia in patients with malignancy

Multilocus Sequence Typing and Further Genetic Characterization of the Enigmatic Pathogen, Staphylococcus hominis

Staphylococcus hominis is a commensal resident of human skin and an opportunistic pathogen. The species is subdivided into two subspecies, S. hominis subsp. hominis and S. hominis subsp. novobiosepticus, which are difficult to distinguish. To investigate the evolution and epidemiology of S. hominis, a total of 108 isolates collected from 10 countries over 40 years were characterized by classica...

epidermidis, ATCC 15305 Staphylococcus saprophyticus, ATCC 35663 Staphylococcus xylosus, ATCC 27840 Staphylococcus capitis subsp. capitis, ATCC 43809 Staphylococcus lugdunensis, ATCC 29970 Staphylococcus haemolyticus, ATCC 27844 Staphylococcus hominis subsp. hominis, and ATCC 43300 methicillin-resistant S. aureus (MRSA). Clinical isolates

Identification of Staphylococcus species with the VITEK 2 system: the case of Staphylococcus hominis.

We read with interest the paper by Layer et al. regarding the identification of staphylococci with automated systems including VITEK-2 (bioMérieux, Marcy l’Etoile, France) (6). Of 86 strains analyzed in their study, 4 were Staphylococcus hominis and all were correctly identified by the colorimetric ID-GP VITEK-2 cards. Identical results have been reported in recent studies evaluating 13 and 14 ...

Methicillin-resistant Staphylococcus aureus and multidrug resistant

The first of these articles reviews the epidemiology of MRSA and its clinical importance in a healthcare setting. The methods of controlling the spread of hospital acquired MRSA are discussed with an emphasis on the role of screening staff for MRSA. Relevant papers for the review were identified by a systematic literature search on Medline. The prevalence of MRSA is increasing in the United Kin...

The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Amikacin has been shown to irreversibly suppressCochlear activity.The aim of this study is to assess the incidence of amikacinototoxicity in multidrug-resistant tuberculosis patients and riskfactors associated withthis ototoxicity.In this cross-sectional study, 41 patientswith multidrug-resistant tuberculosis (MDR-TB) were included.All patients received fixed dose of intravenous amikacin(500 mg...